Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer

Completed · Phase 2/Phase 3

Conditions studied: Hormone Receptor Positive HER-2 Negative Breast Cancer

In brief

This study aims to evaluate the hematological safety of palbociclib with letrozole and fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer. Hematological safety is a composite endpoint of episodes of febrile neutropenia and treatment discontinuation due to neutropenia according to current recommendations for management of neutropenia

Key facts

Study ID
NCT02692755
Run by
Georgetown University
People needed
35
Starts
2016-09-01
Expected to finish
2021-03-23
Last updated by the study team
2021-09-28

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.